DE68911061D1 - Mittel zur Kontrolle von Thrombenbildungen. - Google Patents

Mittel zur Kontrolle von Thrombenbildungen.

Info

Publication number
DE68911061D1
DE68911061D1 DE89115562T DE68911061T DE68911061D1 DE 68911061 D1 DE68911061 D1 DE 68911061D1 DE 89115562 T DE89115562 T DE 89115562T DE 68911061 T DE68911061 T DE 68911061T DE 68911061 D1 DE68911061 D1 DE 68911061D1
Authority
DE
Germany
Prior art keywords
human
csf
control agent
disclosed
thrombus formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE89115562T
Other languages
English (en)
Other versions
DE68911061T2 (de
Inventor
Koichiro Tsuji
Masayoshi Ono
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of DE68911061D1 publication Critical patent/DE68911061D1/de
Application granted granted Critical
Publication of DE68911061T2 publication Critical patent/DE68911061T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Networks Using Active Elements (AREA)
  • Surgical Instruments (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE89115562T 1988-08-24 1989-08-23 Mittel zur Kontrolle von Thrombenbildungen. Expired - Fee Related DE68911061T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21037688 1988-08-24

Publications (2)

Publication Number Publication Date
DE68911061D1 true DE68911061D1 (de) 1994-01-13
DE68911061T2 DE68911061T2 (de) 1994-03-24

Family

ID=16588321

Family Applications (1)

Application Number Title Priority Date Filing Date
DE89115562T Expired - Fee Related DE68911061T2 (de) 1988-08-24 1989-08-23 Mittel zur Kontrolle von Thrombenbildungen.

Country Status (8)

Country Link
US (1) US5202117A (de)
EP (1) EP0355811B1 (de)
KR (1) KR950003492B1 (de)
AT (1) ATE97813T1 (de)
CA (1) CA1339071C (de)
DE (1) DE68911061T2 (de)
IL (1) IL91423A (de)
ZA (1) ZA896463B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120304D0 (en) * 1991-09-24 1991-11-06 Erba Carlo Spa Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
US5879794A (en) * 1994-08-25 1999-03-09 W. L. Gore & Associates, Inc. Adhesive-filler film composite
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
WO1998020528A1 (en) 1996-11-08 1998-05-14 W.L. Gore & Associates, Inc. METHOD FOR IMPROVING RELIABILITY OF THIN CIRCUIT SUBSTRATES BY INCREASING THE Tg OF THE SUBSTRATE
US6776983B1 (en) * 1998-03-06 2004-08-17 Chugai Seiyaku Kabushiki Kaisha Protein free formulations
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
AU2002316201A1 (en) * 2001-06-07 2002-12-16 Quark Biotech, Inc. Methods of using colony stimulating factors in the treatment of tissue damage and ischemia
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
US20090226397A1 (en) * 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
KR100812274B1 (ko) * 2006-10-30 2008-03-13 한양대학교 산학협력단 Ｇ-ｃｓｆ를 유효성분으로 하는 당뇨성 말초신경병 예방 및치료제
EP2094274A4 (de) 2006-12-21 2011-05-11 Biokine Therapeutics Ltd T-140 peptid-analoga mit cxcr4 superagonisten-aktivität für knochenmarkserholung
EP3103880A1 (de) 2008-02-08 2016-12-14 Ambrx, Inc. Modifizierte leptinpolypeptide und deren verwendungen
UA118536C2 (uk) * 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
EP2396023A2 (de) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Kurze peptide aus beta-defensin
CN102481332A (zh) 2009-06-14 2012-05-30 拜欧肯疗法有限公司 用于提高血小板水平的肽疗法
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2841084B1 (de) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptid zur verwendung in der behandlung von lungenkrebs
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
ES2830726T3 (es) 2016-02-23 2021-06-04 Biolinerx Ltd Método para seleccionar un régimen de tratamiento para la leucemia mieloide aguda (LMA)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
EP0644203A1 (de) * 1988-07-29 1995-03-22 Otsuka Pharmaceutical Co., Ltd. IL-1 alpha Derivate und Arzneimittel gegen Thrombozytopenie
JP2805224B2 (ja) * 1989-01-13 1998-09-30 味の素株式会社 血小板減少症治療剤

Also Published As

Publication number Publication date
EP0355811A2 (de) 1990-02-28
KR900002800A (ko) 1990-03-23
US5202117A (en) 1993-04-13
AU625914B2 (en) 1992-07-16
ATE97813T1 (de) 1993-12-15
IL91423A (en) 1995-06-29
IL91423A0 (en) 1990-04-29
EP0355811A3 (de) 1991-03-20
DE68911061T2 (de) 1994-03-24
ZA896463B (en) 1990-05-30
AU4014789A (en) 1990-03-01
EP0355811B1 (de) 1993-12-01
CA1339071C (en) 1997-07-29
KR950003492B1 (ko) 1995-04-13

Similar Documents

Publication Publication Date Title
DE68911061D1 (de) Mittel zur Kontrolle von Thrombenbildungen.
SE8703625D0 (sv) New medical use
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
GEP20002146B (en) Therapeutic Peptide Derivatives
ATE265211T1 (de) Verwendung von porphyrine in der behandlung von multiple sklerose
EP0151989A3 (en) Means for the treatment of cardiac diseases
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
ATE307634T1 (de) Photopherese-behandlung von hcv-infektionen
CA2068069A1 (en) Blood coagulation factor xi concentrate having high specific activity, suitable for therapeutic use, and process for preparing same
FI904403A0 (fi) Fettsyrabehandling.
AU7426487A (en) Method of treating depression using d-fenfluramine
ATE89737T1 (de) Behandlung von leukozytstoerungen mit gm-csf.
EP0388799A3 (de) Verwendung von Human-Beta-Interferon zur Stimulierung der Erythropoiesis
DE69015910D1 (de) Pharmazeutische Verwendung von Fettsäuren.
GR3032224T3 (en) Therapeutic agent for threatened abortion.
DE68916777D1 (de) Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.
NO893256L (no) Fremgangsmaate for fremstilling av furyltiazolderivater.
TWI263502B (en) Pharmaceutical preparation for treating ischemic disease of heart or limbs
GR3000751T3 (en) Tpa-containing medical composition and use thereof
GR3017672T3 (en) Therapeutic agent for diabetic gangrene.
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
DE3876425D1 (de) Gesteuerte verabreichung eines heilmittels an blut.
RU98111356A (ru) Способ лечения ожогового шока
RU94027267A (ru) Способ лечения артериальной ишемии 3 - 4 ст. нижних конечностей при облитерирующих заболеваниях артерий

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee